Dr. Ying Jing, received her Ph.D. in biochemistry and molecular biology from Fudan University and finished postdoctoral training in bioinformatics at the University of Texas Health Science center at Houston. She was a principal investigator at Shanghai Jiao Tong University, School of medicine, and she joined Greater Bay Area Institute of Precision Medicine (Guangzhou) as a principal investigator in 2023. Ying is a computational biologist. Her researches focus on combination of cutting-edge high-throughput sequencing platforms and biological experiment strategies to decipher distinguishable factors for immune related adverse events (irAEs) in cancer patients treated by different kinds of anti-cancer drugs, including immune checkpoint inhibitors, CAR therapies, radiotherapy and target therapy.

1.Radiotherapy-Associated Cellular Senescence and EMT Alterations Contribute to Distinct Disease Relapse Patterns in Locally Advanced Cervical Cancer. Lei Zhang, Jun Ma, Jun Zhang, Minjie Hu, Jinlin Cheng, Bin Hu, Junjun Zhou, Di Zhou, Yongrui Bai, Xiumei Ma*, Jianming Tang*, Haiyan Chen*, Ying Jing*. Advanced Science. 2025 Feb;12:e24125742023.

2.Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Xuwen Lin, Xidong Ma, Sheng Zhao, Jie Yao, Leng Han*, Ying Jing*, Xinying Xue*. Trends Cancer. 2024 Aug;10(10):920-934.

3.Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss. Xiaoqi Yu, Qiming Gong, Demin Yu, Yongyan Chen, Ying Jing*, Fabien Zoulim*, Xinxin Zhang*. Gut. 2024 Apr 5;73(5):797-809.

4.Immune-related adverse events in non-small cell lung cancer: Occurrence, mechanisms and therapeutic strategies. Xuwen Lin, Mei Xie, Jie Yao, Xidong Ma, Lin Qin, Xu-Mei Zhang, Jialin Song, Xinyu Bao, Xin Zhang, Yinguang Zhang, Yiming Liu, Wenya Han, Yiran Liang, Ying Jing*, Xinying Xue*. Clin Transl Med. 2024 Mar;14(3):e1613.

5.The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD. Mei Xie#, Jie Gao#, Xidong Ma, Jialin Song, Chongchong Wu, Yangyu Zhou, Tianjiao Jiang, Yiran Liang, Chen Yang, Xinyu Bao, Xin Zhang, Jie Yao, Ying Jing*, Jianlin Wu, Jianxin Wang, Xinying Xue. BMC Cancer. 2024 Mar 25;24(1):372.

6.Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma. Minjiang Chen#, Pengfei Ma#, Yongchang Zhang#, Dong Wang#, Zhuang Yu, Yujie Fu , Xiaojing Zhao, Mengzhao Wang*, Guanglei Zhuang*, Ying Jing*. J Immunother Cancer, 2023 Oct;11(10):e007305.

7.Single-Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell Cancer Identifies Neural-Like Progenitor Program Associated with the Efficacy of Radiotherapy. Lei Zhang, Jun Ma, Di Zhou, Junjun Zhou, Bin Hu, Xiumei Ma, Jianming Tang*, Yongrui Bai*, Haiyan Chen*, and Ying Jing*. Advanced Science, 2023 Sep;10(25):e2300348.

8.Advancing CAR T-cell therapy through multi-dimensional omics data. Jingwen Yang#, Yamei Chen#, Ying Jing#, Michael R. Green*, Leng Han*. Nature Review Clinical Oncology, 2023 Jan 31

9.Harnessing big data to characterize immune-related adverse events. Ying Jing#, Jingwen Yang#, Douglas B Johnson*, Javid J Moslehi*, Leng Han*. Nature Review Clinical Oncology, 2022 Apr;19(4):269-280;

10.Association of antibiotic treatment with immune-related adverse events in cancer patients receiving immunotherapy. Ying Jing#, Xue Chen#, Kunyan Li#, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H. Lin, Lixia Diao, Jing Wang, YanYan Lou, Douglas B. Johnson, Xiang Chen*, Hong Liu*, Leng Han*. Journal for Immunotherapy of Cancer, 2022, 10(1): e003779

11.Expression of chimeric antigen receptor therapy targets in subpopulations detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Ying Jing#*, Yuan Liu#, Qiang Li, Youqiong Ye, Lixia Diao, Yun Huang, Yubin Zhou, Michael R Green, Gordon B. Mills, Leng Han*. Cancer Cell, 2021 Dec 13; 39(12):1558-1559

12.Association between sex and immune-related adverse events during immune checkpoint inhibitor therapy. Ying Jing#, Yongchang Zhang#, Youqiong Ye, Yaoming Liu, Yanyan Lou, Steven H. Lin, Lixia Diao, Hong Liu, Gordon B. Mills*, Leng Han*. Journal of the National Cancer Institute, 2021 Mar 10; djab035

13.Adverse events associated with potential drugs for COVID-19: a case study from real-world data. Ying Jing*, Lixia Diao*, Leng Han*. Briefings in bioinformatics, 2021 Mar 22; 22(2):1232-1238

14.Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Ying Jing#, Jin Liu#, Youqiong Ye, Lei Pan, Hui Deng, Yushu Wang, Yang Yang, Lixia Diao, Steven H. Lin, Gordon B. Mills, Guanglei Zhuang*, Xinying Xue*, Leng Han*. Nature Communications, 2020 Oct 2; 11(1):4946

15.Baseline immunity and impact of chemotherapy on immune microenviroment in cervical cancer. Yi Zhang#, Minhua Yu#, Ying Jing#, Jiejun Cheng, Caiyan Zhang, Lin Cheng, Haijiao Lu, Mei-chun Cai, Jie Wu, Wenjing Wang, Weihua Lou, Lihua Qiu, Li Tan, Huaiwu Lu, Xia Yin, Guanglei Zhuang*, Wen Di*. British Journal of Cancer, 2021 Jan; 124(2):414-424

16.Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer. Ying Jing#, Yi Zhang#, Hui Zhu#, Ke Zhang, Mei-Chun Cai, Pengfei Ma, Peiye Shen, Zhenfeng Zhang, Minghui Shao, Jing Wang, Minhua Yu, Xia Yin, Meiying Zhang, Yuan Hu, Danni Chen, Wen Di, Xiaojie Wang*, Guanglei Zhuang*. Oncogene, 2019 April; 38(16):3047-3060

17.Prevalence and clonality of synchronous primary carcinomas in the bladder and prostate. Ying Jing#, Ruiyun Zhang#, Pengfei Ma, Mei-Chun Cai, Guanglei Zhuang*, Haige Chen*. Journal of Pathology, 2018 Jan; 244(1):5-10

18.Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Peiye Shen#, Ying Jing#, Ruiyun Zhang#, Mei-chun Cai, Pengfei Ma, Haige Chen*, Guanglei Zhuang*. Oncogene, 2018 May; 37(22):3039-3044

19.Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Shengzhe Zhang#, Meiying Zhang#, Ying Jing#, Xia Yin, Pengfei Ma, Zhenfeng Zhang, Xiaojie Wang, Wen Di, Guanglei Zhuang*. Nature Communications, 2018 Jan; 9(1):215

20.Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer. Xia Yin#, Ying Jing#, Mei-Chun Cai#, Pengfei Ma, Yi Zhang, Cong Xu, Meiying Zhang, Wen Di*, Guanglei Zhuang*. Cancer Research, 2017 Dec 1; 77(23):6551-6561

21.BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by downregulating FoxM1. Zhenfeng Zhang#, Pengfei Ma#, Ying Jing#, Ying Yan, Mei-chun Cai, Meiying Zhang, Shengzhe Zhang, Huixin Peng, Zhi-liang Ji, Wen Di, Zhenyu Gu, Wei-Qiang Gao*, Guanglei Zhuang*. Theranostics, 2016; 6(2):219-30

22.Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Deshui Jia#, Rui Dong#, Ying Jing#, Dan Xu#, Qifeng Wang, Lei Chen, Qigen Li, Yuping Huang, Yuannv Zhang, Zhenfeng Zhang, Li Liu, Shan Zheng, Qiang Xia, Hongyang Wang, Kuiran Dong*, Xianghuo He*. Hepatology, 2014; 60(5): 1686-9

23.SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma. Ying Jing#, Deshui Jia#, Chun-Ming Wong, Irene Oi-Lin Ng, Zhenfeng Zhang, Li Liu, Qifeng Wang, Fangyu Zhao, Jinjun Li, Ming Yao, Xingzhong Wu*, Xianghuo He*. Molecular Oncology, 2014; 8(2):366-77